Impact of national heart, lung, and blood institute-supported cardiovascular epidemiology research, 1998 to 2012

Circulation

Volumn 132, Issue 21, 2015, Pages 2028-2033

  Fabsitz, Richard R ^a   Papanicolaou, George J ^a   Sholinsky, Phyliss ^a   Coady, Sean A ^a   Jaquish, Cashell E ^a   Nelson, Cheryl R ^a   Olson, Jean L ^a   Puggal, Mona A ^a   Purkiser, Kevin L ^a   Srinivas, Pothur R ^a   Wei, Gina S ^a   Wolz, Michael ^a   Sorlie, Paul D ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

epidemiology; evaluation; health impact assessment; National Heart, Lung, and Blood Institute (U.S.); population characteristics; population dynamics; risk factors

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; EPIDEMIOLOGICAL DATA; GENETICS; HEALTH CARE QUALITY; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; PUBLICATION; MANPOWER; ORGANIZATION AND MANAGEMENT;

BIOMEDICAL RESEARCH; HUMANS;

EID: 84947997842     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.014147     Document Type: Article

References (22)

1. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A. 2014; 111: 5773-5777. doi: 10.1073/pnas.1404402111.
2. Rosbash M A threat to medical innovation. Science. 2011; 333: 136. doi: 10.1126/science.1210374.
3. Chakma J, Sun GH, Steinberg JD, Sammut SM, Jagsi R. Asia's ascent-global trends in biomedical R&D expenditures. N Engl J Med. 2014; 370: 3-6. doi: 10.1056/NEJMp1311068.
4. Langer JS. Enabling scientific innovation. Science. 2012; 338: 171. doi: 10.1126/science.1230947.
5. Zoghbi HY. The basics of translation. Science. 2013; 339: 250. doi: 10.1126/science.1234799.
6. Mervis J. Peering into peer review. Science. 2014; 343: 596-598. doi: 10.1126/science.343.6171.596.
7. Casadevall A, Fang FC. Reforming science: methodological and cultural reforms. Infect Immun. 2012; 80: 891-896. doi: 10.1128/IAI.06183-11.
8. Danthi N, Wu CO, Shi P, Lauer M. Percentile ranking and citation impact of a large cohort of National Heart, Lung, and Blood Institute-funded cardiovascular R01 grants. Circ Res. 2014; 114: 600-606. doi: 10.1161/.CIRCRESAHA.114.302656.
9. Ioannidis JP. More time for research: fund people not projects. Nature. 2011; 477: 529-531. doi: 10.1038/477529a.
10. Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013; 22: 508-516. doi: 10.1158/1055-9965.EPI-13-0146.
11. Lauer MS. Thought exercises on accountability and performance measures at the National Heart, Lung, and Blood Institute (NHLBI): an invited commentary for circulation research. Circ Res. 2011; 108: 405-409. doi: 10.1161/RES.0b013e3182125662.
12. Sorlie PD, Bild DE, Lauer MS. Cardiovascular epidemiology in a changing world-challenges to investigators and the National Heart, Lung, and Blood Institute. Am J Epidemiol. 2012; 175: 597-601. doi: 10.1093/aje/.kws138.
13. Lauer MS. Time for a creative transformation of epidemiology in the United States. JAMA. 2012; 308: 1804-1805. doi: 10.1001/jama.2012.14838.
14. Sorlie P, Wei GS. Population-based cohort studies: still relevant? J Am Coll Cardiol. 2011; 58: 2010-2013. doi: 10.1016/j.jacc.2011.08.020.
15. Puggal MA, Schully SD, Srinivas PR, Papanicolaou GJ, Jaquish CE, Fabsitz RR. Translation of genetics research to clinical medicine: the National Heart, Lung, and Blood Institute perspective. Circ Cardiovasc Genet. 2013; 6: 634-639. doi: 10.1161/CIRCGENETICS.113.000227.
16. Oh YS, Galis ZS. Anatomy of success: the top 100 cited scientific reports focused on hypertension research. Hypertension. 2014; 63: 641-647. doi: 10.1161/HYPERTENSIONAHA.113.02677.
17. Gordon D, Taddei-Peters W, Mascette A, Antman M, Kaufmann PG, Lauer MS. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2013; 369: 1926-1934. doi: 10.1056/.NEJMsa1300237.
18. Galis ZS, Hoots WK, Kiley JP, Lauer MS. On the value of portfolio diversity in heart, lung, and blood research. Am J Respir Crit Care Med. 2012; 186: 575-578. doi: 10.1164/rccm.201208-1437ED.
19. Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw JE, Anderson GL, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med. 2014; 160: 594-602. doi: 10.7326/M13-2348.
20. Ioannidis JP, Tarone R, McLaughlin JK. The false-positive to false-negative ratio in epidemiologic studies. Epidemiology. 2011; 22: 450-456. doi: 10.1097/EDE.0b013e31821b506e.
21. Lenfant C. Shattuck lecture-clinical research to clinical practice-lost in translation? N Engl J Med. 2003; 349: 868-874. doi: 10.1056/.NEJMsa035507.
22. O'Donnell CJ, Nabel EG. Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era. Circ Cardiovasc Genet. 2008; 1: 51-57. doi: 10.1161/.CIRCGENETICS.108.813337.